Retrospective Study
Copyright ©The Author(s) 2020.
World J Hepatol. Nov 27, 2020; 12(11): 1031-1045
Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1031
Figure 5
Figure 5 Overall survival analysis in hepatocellular carcinoma patients in relation to serum hsa-miR-21-5p, hsa-miR-122-5p, and alpha-fetoprotein levels. A: Correlation between serum hsa-miR-21-5p (miR-21) and serum hsa-miR-122-5p (miR-122); B: All patients were divided into three groups: Both miR-21 and miR-122 low (50th percentile, n = 28); one of miR-21 or miR-122 low (50th percentile, n = 37); both miR-21 and miR-122 high (> 50th percentile, n = 26); C: Analysis of overall survival of alpha-fetoprotein (AFP) low (n = 24) vs AFP high (n = 23) in patients with low miR-21 levels; and D: Analysis of overall survival of AFP low (n = 22) vs AFP high (n = 22) in patients with high miR-21 levels. Spearman correlation and nonparametric log-rank test were used for statistical analysis. MiR-21: Hsa-miR-21-5p; MiR-122: Hsa-miR-122-5p.